Appili Therapeutics Inc Class A (APLI) AI Stock Analysis

• Market Cap: C$3.03M
• Dividend Yield: N/A
• Average Volume (3M): 72.91K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.17
• Revenue Growth: -58.01%
• EPS Growth: 29.73%
• Country: CA
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 121,266,120
• 10 Day Avg. Volume: 40,186
• 30 Day Avg. Volume: 72,908
• PEG Ratio: 0.02
• Price to Book (P/B): -0.39
• Price to Sales (P/S): 5.13
• P/FCF Ratio: -1.70
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: C$0.03 ▲(30.00% Upside)

The overall stock score reflects significant financial challenges, with high leverage and unprofitability weighing heavily. However, the company's strategic success in securing substantial funding and advancing its programs provides a positive outlook. Technical indicators suggest stability, but valuation remains a concern due to negative earnings.

Positive Factors

Strategic Partnerships

Securing a $40M contract with NIAID highlights Appili's ability to form strategic partnerships, enhancing its R&D capabilities and potential revenue streams.

Product Development

Participation in the BARDA Symposium underscores Appili's commitment to innovation in biodefense, potentially leading to new market opportunities and product advancements.

Funding Initiatives

The private placement aims to raise C$750,000, providing essential capital for working capital and product development, supporting long-term operational stability.

Negative Factors

Financial Instability

Negative equity and high leverage indicate financial instability, posing risks to sustainability and limiting the company's ability to invest in growth.

Revenue Decline

A sharp revenue decline highlights challenges in market demand or competitive positioning, impacting long-term profitability and growth prospects.

Unprofitability

Persistent unprofitability reflects operational inefficiencies and challenges in achieving sustainable margins, threatening long-term financial health.

Appili Therapeutics Inc Class A Business Overview & Revenue Model

Company Description

Appili Therapeutics Inc. is a biotechnology company focused on developing novel antimicrobial and antiviral therapies. The company operates primarily in the pharmaceutical sector, concentrating on addressing unmet medical needs related to infectious diseases. Appili's core products include its leading candidate, ATI-1501, which is an oral formulation of the antibiotic metronidazole, aimed at treating infections caused by Clostridium difficile. The company is also engaged in other projects focusing on the development of therapies for resistant bacterial infections and viral diseases.

How the Company Makes Money

Appili Therapeutics generates revenue primarily through the development and commercialization of its pharmaceutical products. The company earns money by securing funding from government grants, partnerships, and collaborations with larger pharmaceutical companies that provide resources and capital to support its research and development efforts. Additionally, Appili may receive milestone payments and royalties from partners upon the successful development and commercialization of their products. Their revenue model is further supported by potential sales of their therapies once they receive regulatory approval and are brought to market.

Appili Therapeutics Inc Class A Financial Statement Overview

Summary

Appili Therapeutics Inc Class A is facing substantial financial challenges, with consistent unprofitability, high leverage, and negative equity. While there are slight improvements in cash flow, the company's financial health is concerning. Continued efforts to improve revenue generation and manage debt are crucial for long-term viability.

Income Statement

Appili Therapeutics Inc Class A has faced significant challenges in revenue generation, with a substantial decline of 87.86% in revenue from 2024 to 2025. The company has consistently reported negative net income and EBIT over the years, indicating persistent unprofitability. Gross profit margins remain at 100% due to revenue matching the cost, but the overall profitability is severely impacted by high operating losses.

Balance Sheet

The company exhibits high leverage with a negative stockholders' equity, resulting in an undefined debt-to-equity ratio. The equity ratio is also negative, reflecting more liabilities than assets. This financial instability poses significant risks to the company's sustainability and future operations.

Cash Flow

Appili has demonstrated some improvement in cash flow management with a positive operating cash flow in 2025. However, the free cash flow remains volatile, with a sharp negative trajectory in previous years. The operating cash flow to net income ratio is not favorable due to continuous negative net income, indicating challenges in converting revenue into cash.

Breakdown	TTM	Dec 2024	Dec 2024	Dec 2023	Dec 2022	Dec 2020
Income Statement
Total Revenue	199.69K	100.44K	827.41K	334.18K	1.39M	0.00
Gross Profit	188.75K	100.44K	827.41K	327.91K	1.39M	-14.84K
EBITDA	-881.13K	360.57K	-2.07M	-8.10M	-23.51M	-14.87M
Net Income	-2.53M	-2.62M	-3.78M	-9.24M	-25.12M	-14.33M
Balance Sheet
Total Assets	754.46K	3.03M	1.49M	3.13M	8.28M	18.32M
Cash, Cash Equivalents and Short-Term Investments	348.68K	1.23M	94.49K	2.47M	6.66M	16.12M
Total Debt	12.22M	12.29M	8.18M	7.67M	4.98M	1.03M
Total Liabilities	16.36M	16.43M	12.42M	10.53M	11.55M	5.56M
Stockholders Equity	-15.61M	-13.40M	-10.92M	-7.40M	-3.27M	12.75M
Cash Flow
Free Cash Flow	-174.57K	866.46K	-2.49M	-10.10M	-19.08M	-11.46M
Operating Cash Flow	-173.87K	868.82K	-2.46M	-10.10M	-19.08M	-11.45M
Investing Cash Flow	-702.00	-2.36K	-29.06K	-3.17K	5.06M	-4.99M
Financing Cash Flow	-221.47K	193.68K	122.05K	5.91M	9.56M	17.02M

Appili Therapeutics Inc Class A Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:APLI, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.03, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.39 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:APLI.

Appili Therapeutics Inc Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APLI	55 Neutral	C$3.03M	-1.20	―	―	-58.01%	29.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRVL	22 Underperform	C$8.99M	-3.44	―	―	―	―

Appili Therapeutics Inc Class A Corporate Events

Appili Therapeutics Reports Strong Q2 Results and Secures Major Funding for Infectious Disease Programs

Appili Therapeutics has announced its financial and operational results for the second quarter of fiscal year 2026, highlighting a significant non-dilutive funding award of up to US$40 million from the NIAID for its VXV-01 program. The company is actively pursuing additional funding proposals worth US$90 million to support various development activities. Appili’s strategic approach to securing government contracts and grants has already resulted in over US$66 million in funding, positioning the company to advance its infectious disease and biodefense programs while maintaining financial flexibility. The re-launch of LIKMEZ® in the U.S. market has shown increasing sales, and the company is progressing with its ATI-1801 and ATI-1701 programs, with the latter achieving key manufacturing milestones and promising data presentations.

Appili Therapeutics Launches C$750,000 Private Placement to Boost Drug Development

Appili Therapeutics announced a non-brokered private placement to raise up to C$750,000 through the issuance of 30 million units, each consisting of a common share and a warrant. The funds will be used for working capital and product development, with the placement subject to regulatory approvals and shareholder consent for warrant exercisability. This move is expected to support the company’s ongoing efforts in drug development and strengthen its financial position.

Appili Therapeutics to Showcase Biodefense Innovations at BARDA Symposium

Appili Therapeutics announced its participation in the BARDA Innovation Symposium 2025, highlighting its government-funded pipeline and the role of public-private partnerships in biodefense innovation. The company has secured a contract worth up to $40 million from NIAID for developing a fungal vaccine candidate and submitted proposals for additional federal funding. These efforts underscore Appili’s strategy of leveraging non-dilutive government funding to advance its anti-infective programs, reinforcing its position as a trusted partner in national biodefense priorities.

Appili Therapeutics Secures $40 Million Contract for Fungal Vaccine Development

Appili Therapeutics, in partnership with Vitalex Biosciences, has been awarded a contract by the National Institute of Allergy and Infectious Diseases valued at up to $40 million to develop a novel fungal vaccine, VXV-01. This contract supports the vaccine’s development through Phase 1 clinical trials, aiming to address the significant health burden posed by invasive fungal infections, which affect millions globally. The vaccine is expected to provide robust immunity against pathogens like Candida species, representing a major advancement in fungal disease prevention. Additionally, Appili has submitted further funding proposals to the U.S. government, potentially securing up to $97 million to support the development of critical infectious disease products.

Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives

Appili Therapeutics announced the results of its annual and special meeting of shareholders, where all proposed resolutions were approved, including the election of directors and the re-appointment of PricewaterhouseCoopers as the independent auditor. The approval of unallocated options and awards under the company’s stock option and equity incentive plans was also confirmed, indicating strong shareholder support for Appili’s strategic direction.

Appili Therapeutics to Showcase Tularemia Vaccine at NATO Conference

Appili Therapeutics announced that Dr. Carl Gelhaus will present the progress of their ATI-1701 biodefense vaccine at the NATO CBRN Conference. The vaccine is designed to protect against tularemia, a significant biological threat to NATO forces, and aims to fill a strategic gap in biodefense preparedness. Supported by the U.S. Air Force Academy, ATI-1701 could become the first FDA-approved vaccine for tularemia, highlighting its potential impact on global biodefense efforts.